International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship
ABSTRACT Background In this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries.Methods We retrospectively collected de-identified data on a cohort of cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, from 16 international centers.Results We analyzed 3966 COVID-19 confirmed patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were more likely to be pancytopenic, and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding two weeks (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms (p≤0.01). By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to6.20; p< 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30-day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who did not (5.9% vs 17.6%; p=0.03).Conclusions Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality.Condensed Abstract In this large multicenter worldwide study of 4015 patients with COVID-19 that included 1115 patients with cancer, we found that cancer is an independent risk factor for increased 30-day all-cause mortality. Remdesivir is a promising treatment modality to reduce 30-day all-cause mortality..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.08.25.22279181 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI037095838 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI037095838 | ||
| 003 | DE-627 | ||
| 005 | 20240424105226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220901s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.08.25.22279181 |2 doi | |
| 035 | |a (DE-627)XBI037095838 | ||
| 035 | |a (biorXiv)10.1101/2022.08.25.22279181 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Raad, Issam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background In this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries.Methods We retrospectively collected de-identified data on a cohort of cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, from 16 international centers.Results We analyzed 3966 COVID-19 confirmed patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were more likely to be pancytopenic, and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding two weeks (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms (p≤0.01). By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to6.20; p< 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30-day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who did not (5.9% vs 17.6%; p=0.03).Conclusions Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day all-cause mortality.Condensed Abstract In this large multicenter worldwide study of 4015 patients with COVID-19 that included 1115 patients with cancer, we found that cancer is an independent risk factor for increased 30-day all-cause mortality. Remdesivir is a promising treatment modality to reduce 30-day all-cause mortality. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Hachem, Ray |e verfasserin |4 aut | |
| 700 | 1 | |a Masayuki, Nigo |e verfasserin |4 aut | |
| 700 | 1 | |a Datoguia, Tarcila |e verfasserin |4 aut | |
| 700 | 1 | |a Dagher, Hiba |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |0 (orcid)0000-0002-6064-6837 |4 aut | |
| 700 | 1 | |a Siddiqui, Bilal |e verfasserin |4 aut | |
| 700 | 1 | |a Bayle, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Somer, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, Ana Fernández |e verfasserin |4 aut | |
| 700 | 1 | |a Gorak, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Bhinder, Arvinder |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Nobuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hamerschlak, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Shelanski, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Dragivich, Tomislav |e verfasserin |4 aut | |
| 700 | 1 | |a Kiat, Yee Elise Vong |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhreddine, Suha |e verfasserin |4 aut | |
| 700 | 1 | |a Hanna, Pierre Abi |e verfasserin |4 aut | |
| 700 | 1 | |a Chemaly, Roy F. |e verfasserin |4 aut | |
| 700 | 1 | |a Mulanovich, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Adachi, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Borjan, Jovan |e verfasserin |4 aut | |
| 700 | 1 | |a Khawaja, Fareed |e verfasserin |4 aut | |
| 700 | 1 | |a Granwehr, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a John, Teny |e verfasserin |4 aut | |
| 700 | 1 | |a Guevara, Eduardo Yepez |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Harrys |e verfasserin |4 aut | |
| 700 | 1 | |a Ammakkanavar, Natraj Reddy |e verfasserin |4 aut | |
| 700 | 1 | |a Yibirin, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes-Gibby, Cielito C |e verfasserin |4 aut | |
| 700 | 1 | |a Pande, Mala |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Noman |e verfasserin |4 aut | |
| 700 | 1 | |a Rojo, Raniv Dawey |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Shahnoor M |e verfasserin |4 aut | |
| 700 | 1 | |a Deeba, Rita E |e verfasserin |4 aut | |
| 700 | 1 | |a Chaftari, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuo, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Aguado-Noya, Ramón |e verfasserin |4 aut | |
| 700 | 1 | |a García-García, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Puchol, Cristina Traseira |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Dong-Gun |e verfasserin |4 aut | |
| 700 | 1 | |a Slavin, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Teh, Benjamin |e verfasserin |0 (orcid)0000-0003-0213-5470 |4 aut | |
| 700 | 1 | |a Arias, Cesar A |e verfasserin |4 aut | |
| 700 | 1 | |a Kontoyiannis, Dimitrios P. |e verfasserin |4 aut | |
| 700 | 1 | |a Malek, Alexandre E. |e verfasserin |4 aut | |
| 700 | 1 | |a Chaftari, Anne-Marie |e verfasserin |0 (orcid)0000-0001-8097-8452 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.7554/elife.81127 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.08.25.22279181 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||